High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.

Abstract

INTRODUCTION:

T cells occupy a central role in MS and CIDP pathogenesis. High dose cyclophosphamide's in-vivo cytotoxic-effect on circulating memory and naïve T cells is unknown.

METHOD:

Three MS and five CIDP patients received cyclophosphamide (200 mg/kg) for refractory disease. Before and after chemotherapy administration, peripheral blood T-cell subsets were determined. Patients underwent serial neurologic evaluations quarterly.

RESULTS:

Cyclophosphamide uniformly decreased clinical disease activity. Compared to memory T cells, naïve T cells were preferentially eradicated.

DISCUSSION:

Cyclophosphamide effectiveness in autoimmune illness may result from Naïve T-cell destruction, as this compartment may be the source of autoreactive lymphocytes.

• Authors: Douglas E Gladstone, Marc G Golightly, Thomas H Brannagan 3rd
• Journal: Journal of neuroimmunology (J Neuroimmunol) Vol. 190 Issue 1-2 Pg. 121-6 (Oct 2007) ISSN: 0165-5728 [Print] Netherlands
• PMID: 17854912 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Immunosuppressive Agents
• Cyclophosphamide
• Leukocyte Common Antigens
• PTPRC protein, human

Topics

• Adult
• CD4 Lymphocyte Count
• CD4-Positive T-Lymphocytes (drug effects, immunology)
• Cyclophosphamide (pharmacology)
• Dose-Response Relationship, Drug
• Female
• Humans
• Immunologic Memory (drug effects, immunology)
• Immunosuppressive Agents (pharmacology)
• Leukocyte Common Antigens (immunology)
• Lymphocyte Activation (drug effects, immunology)
• Male
• Middle Aged
• Multiple Sclerosis (drug therapy, immunology, physiopathology)
• Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (drug therapy, immunology, physiopathology)
• Recovery of Function (drug effects, immunology)
• T-Lymphocytes (drug effects, immunology)
• Treatment Outcome